Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.
Susan F. Slovin(Cornell University), Howard I. Scher(Memorial Sloan Kettering Cancer Center), J. Mendelsohn, William Kevin Kelly(Thomas Jefferson University), P O Livingston(Memorial Sloan Kettering Cancer Center), Neal Rosen(Memorial Sloan Kettering Cancer Center), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States))
PubMed
December 1, 1996
Cited by 19
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k